FibroGen, Inc. (BMV:FGEN)
6.18
-0.19 (-2.98%)
Last updated: May 13, 2025
FibroGen Statistics
Total Valuation
FibroGen has a market cap or net worth of MXN 606.01 million. The enterprise value is 2.21 billion.
Market Cap | 606.01M |
Enterprise Value | 2.21B |
Important Dates
The last earnings date was Monday, May 5, 2025.
Earnings Date | May 5, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | 101.04M |
Shares Outstanding | n/a |
Shares Change (YoY) | +2.82% |
Shares Change (QoQ) | +0.31% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 92.73M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 4.24 |
PB Ratio | -0.17 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -10.80 |
EV / Sales | 3.80 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.02
Current Ratio | 2.02 |
Quick Ratio | 0.46 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -11.48 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -22.73% |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | -105.17% |
Revenue Per Employee | 635,514 |
Profits Per Employee | -909,031 |
Employee Count | 225 |
Asset Turnover | 0.03 |
Inventory Turnover | 5.91 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.41% in the last 52 weeks. The beta is 0.88, so FibroGen's price volatility has been lower than the market average.
Beta (5Y) | 0.88 |
52-Week Price Change | -69.41% |
50-Day Moving Average | 6.89 |
200-Day Moving Average | 8.70 |
Relative Strength Index (RSI) | 46.95 |
Average Volume (20 Days) | 244 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FibroGen had revenue of MXN 142.99 million and -204.53 million in losses. Loss per share was -2.03.
Revenue | 142.99M |
Gross Profit | -1.70B |
Operating Income | -1.97B |
Pretax Income | -2.47B |
Net Income | -204.53M |
EBITDA | -1.92B |
EBIT | -1.97B |
Loss Per Share | -2.03 |
Balance Sheet
The company has 686.93 million in cash and 1.86 billion in debt, giving a net cash position of -1.18 billion.
Cash & Cash Equivalents | 686.93M |
Total Debt | 1.86B |
Net Cash | -1.18B |
Net Cash Per Share | n/a |
Equity (Book Value) | -3.58B |
Book Value Per Share | -43.91 |
Working Capital | 1.54B |
Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | n/a |
Operating Margin | -1,380.42% |
Pretax Margin | -1,730.87% |
Profit Margin | -143.04% |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
FibroGen does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -2.82% |
Shareholder Yield | -2.82% |
Earnings Yield | -33.75% |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |